DK1370288T3 - Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG - Google Patents

Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG

Info

Publication number
DK1370288T3
DK1370288T3 DK01996390.9T DK01996390T DK1370288T3 DK 1370288 T3 DK1370288 T3 DK 1370288T3 DK 01996390 T DK01996390 T DK 01996390T DK 1370288 T3 DK1370288 T3 DK 1370288T3
Authority
DK
Denmark
Prior art keywords
thrombocytopenia
ivig
monoclonal
producing
composition
Prior art date
Application number
DK01996390.9T
Other languages
English (en)
Inventor
Alan H Lazarus
John Freedman
Seng Song
Andrew R Crow
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Application granted granted Critical
Publication of DK1370288T3 publication Critical patent/DK1370288T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
DK01996390.9T 2000-11-20 2001-11-20 Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG DK1370288T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24944100P 2000-11-20 2000-11-20
PCT/CA2001/001648 WO2002040047A2 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Publications (1)

Publication Number Publication Date
DK1370288T3 true DK1370288T3 (da) 2012-03-05

Family

ID=22943488

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10178480.9T DK2283861T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig
DK01996390.9T DK1370288T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10178480.9T DK2283861T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig

Country Status (7)

Country Link
US (1) US20040047862A1 (da)
EP (2) EP1370288B1 (da)
AT (1) ATE540694T1 (da)
AU (1) AU2002220404A1 (da)
CA (2) CA2856033C (da)
DK (2) DK2283861T3 (da)
WO (1) WO2002040047A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
WO2005094880A1 (en) * 2004-03-30 2005-10-13 Canadian Blood Services Method for treating autoimmune diseases with antibodies
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8597636B2 (en) 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
EP3456351A1 (en) 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US7846744B2 (en) 2008-04-22 2010-12-07 Ravetch Jeffrey V Methods of identifying anti-inflammatory compounds
US20150329639A1 (en) * 2012-12-12 2015-11-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
CN112142843A (zh) 2013-12-24 2020-12-29 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
MX2017011534A (es) 2015-03-09 2018-04-10 Argenx Bvba Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
MA56102A (fr) 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
AU2021206547A1 (en) 2020-01-08 2022-07-14 argenx BV Methods for treating pemphigus disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JPH0987202A (ja) * 1995-09-20 1997-03-31 Sumitomo Pharmaceut Co Ltd 血液凝固異常治療剤
AU8266798A (en) * 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
PL200134B1 (pl) * 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells

Also Published As

Publication number Publication date
US20040047862A1 (en) 2004-03-11
EP1370288B1 (en) 2012-01-11
EP2283861A2 (en) 2011-02-16
CA2467781A1 (en) 2002-05-23
DK2283861T3 (da) 2016-02-15
WO2002040047A2 (en) 2002-05-23
CA2467781C (en) 2014-09-23
ATE540694T1 (de) 2012-01-15
CA2856033A1 (en) 2002-05-23
WO2002040047A3 (en) 2003-10-02
CA2856033C (en) 2015-11-03
EP2283861A3 (en) 2013-05-29
EP2283861B1 (en) 2016-01-27
EP1370288A2 (en) 2003-12-17
AU2002220404A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
DK1370288T3 (da) Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
IL267186A (en) Epitopes of regulated T cells, preparations and uses
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
NZ626665A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
JP2003534781A5 (da)
ATE447587T1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
NZ601583A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
TW200716182A (en) Antibodies directed to CD20 and uses thereof
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
DE60236016D1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
ATE419009T1 (de) Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
MY159517A (en) A monoclonal antibody and a method thereof
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
BR0207151A (pt) Moléculas de aglutinação terapêuticas
DE60328747D1 (de) Reinigung von polyreaktiven Autoantikörpern und deren Verwendungen
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
RU2019103991A (ru) Анти-il-22r-антитела